ADHD Medication Shortage Australia: What's Affected (2026)

If you've stood at a pharmacy counter and been told your ADHD medication is out of stock, you know how destabilising it is. It's not like running out of paracetamol — for many people, these medications are the difference between a functional day and a non-functional one. Australia has experienced recurring shortages of ADHD medications since late 2023, and supply disruptions continue into 2026.

This is not a one-off event. The shortages are driven by structural issues — global manufacturing capacity has not kept pace with rapidly growing demand for ADHD medications. In Australia, PBS prescriptions for ADHD stimulant medications more than doubled from approximately 1.4 million in 2019–20 to over 3.1 million in 2023–24 (AIHW data). Similar demand growth has occurred in the US, UK, and Europe, creating worldwide pressure on the same manufacturing supply chains.

The 2023 Australian Senate inquiry into ADHD heard extensive evidence about the impact of medication shortages on patients. Witnesses described being forced to switch medications at short notice, driving between multiple pharmacies to find stock, and experiencing treatment interruptions that affected their work, relationships, and mental health. The Senate committee's report acknowledged medication supply as a significant concern.

The core problem: Global production of active pharmaceutical ingredients (APIs) for ADHD stimulants is controlled by a small number of manufacturers, and production quotas in countries like the US create bottleneck effects that ripple through international supply chains. Australia, as a relatively small market, is particularly vulnerable to these disruptions.

The following ADHD medications have experienced supply disruptions in Australia since 2023:

• Lisdexamfetamine (Vyvanse):**
• The most commonly prescribed ADHD medication in Australia
• Multiple shortage notifications from the TGA
• Specific dose strengths (particularly 30mg and 50mg capsules) have been intermittently unavailable
• Generic lisdexamfetamine brands have helped but have also experienced supply issues

• Methylphenidate (Ritalin, Ritalin LA, Concerta):**
• Short-acting methylphenidate (Ritalin 10mg) has experienced periodic shortages
• Long-acting formulations (Concerta, Ritalin LA) have been more consistently available but not immune
• Generic methylphenidate brands have partially offset supply gaps

• Dexamfetamine:**
• As a Schedule 8 controlled substance with limited manufacturers, dexamfetamine is vulnerable to shortages
• Shortages of immediate-release dexamfetamine tablets have been reported, particularly in regional areas

• Guanfacine (Intuniv):**
• Non-stimulant option that has experienced some supply disruption
• Less widely prescribed, so shortages attract less attention but still affect patients

• Atomoxetine (Strattera):**
• Generally more stable supply than stimulant medications
• Has been used as an alternative when stimulants are unavailable, increasing demand

The ADHD medication shortage is driven by multiple intersecting factors:

1. Explosive demand growth Australian PBS data shows ADHD medication prescriptions grew by more than 25% per year between 2020 and 2024. This growth reflects increased awareness, better diagnosis (particularly in adults and women), and expanded PBS listings — not over-prescribing. But manufacturers did not anticipate this growth rate and production capacity lags behind.

2. Global API supply constraints The active pharmaceutical ingredients (APIs) for stimulant medications are manufactured by a small number of facilities worldwide. Production is subject to regulatory quotas in key manufacturing countries (notably the US DEA production quotas for Schedule II substances). When the US experiences shortages, the ripple effects reach Australia within months.

3. PBS listing expansion The PBS expanded coverage of lisdexamfetamine (Vyvanse) to adults in 2023, significantly increasing the eligible patient population. While this was a welcome policy change that improved access, it created a step-change in demand that the supply chain was not prepared for.

4. Limited buffer stock Australia holds relatively small buffer stocks of controlled substances compared to other essential medications. The "just in time" pharmaceutical supply chain works well under normal conditions but is fragile when disruptions occur.

5. Regulatory complexity Stimulant medications are Schedule 8 controlled substances with strict regulatory requirements around manufacturing, import, storage, and distribution. These regulations serve important safety purposes but reduce supply chain flexibility and make it harder to respond quickly to shortages.

6. Small market disadvantage Australia represents a small fraction of the global ADHD medication market. When global supply is constrained, larger markets (US, EU) tend to be prioritised by manufacturers, and smaller markets like Australia feel the impact disproportionately.

Running out of medication is stressful, and the logistics of chasing stock across pharmacies is the exact kind of task ADHD makes harder. Here are the most practical steps, in order of what to try first:

Immediate actions:

• Ask your pharmacist to check other branches — stock levels vary between pharmacies and between regions. Your pharmacist can check availability at other locations in their network.
• Try other pharmacies — if your pharmacy is part of a chain (Chemist Warehouse, Priceline, TerryWhite), other locations may have stock. Independent pharmacies sometimes have different supply chains.
• Ask about alternative brands — if the branded version is unavailable, a generic equivalent may be in stock. For example, generic lisdexamfetamine may be available when Vyvanse is not. Your pharmacist can dispense a different brand without a new prescription if the active ingredient and dose are the same.
• Use eScript flexibility — if you have an electronic prescription, you are not locked to one pharmacy. You can present your eScript at any pharmacy in Australia.

If no stock is available anywhere:

• Contact your prescriber — your psychiatrist or GP can advise on temporary alternatives. Options may include switching to a different medication in the same class, adjusting the formulation (e.g., short-acting instead of long-acting), or bridging with a non-stimulant medication.
• Do not abruptly stop — while ADHD stimulants are not physically addictive in the way opioids are, abrupt cessation can cause significant rebound symptoms including fatigue, depression, and worsened ADHD symptoms. Tapering or switching is preferable.
• Document the shortage — report supply issues to the TGA's Medicine Shortage Reports database. Patient reports help the TGA monitor and respond to shortages.

Preventive measures:

• Maintain a 2–3 week buffer supply — fill prescriptions before you run out completely, not after. Talk to your prescriber about slightly overlapping script dates to build a buffer.
• Set pharmacy alerts — many pharmacies can notify you when a medication comes back in stock.
• Discuss a backup plan with your prescriber proactively — know what alternative medication you would switch to if your primary is unavailable.

If you're unsure whether you're paying the right amount for your medication, or you're on a private script when you could be on PBS, see our PBS guide.

If your primary ADHD medication is unavailable, your prescriber may recommend one of the following alternatives. All require a prescription and most are PBS-listed:

Stimulant alternatives:

Non-stimulant alternatives:

• Atomoxetine (Strattera) — selective noradrenaline reuptake inhibitor. Takes 4–6 weeks to reach full effect. PBS-listed for ADHD.
• Guanfacine (Intuniv) — alpha-2 adrenergic agonist. PBS-listed for children/adolescents; off-label use in adults. Can be used alone or alongside stimulants.
• Clonidine — similar mechanism to guanfacine. Less commonly used for ADHD in Australia but available.

Important considerations when switching:

• Switching between stimulant classes (amphetamine-based to methylphenidate-based or vice versa) is common and safe but requires re-titration to find the right dose.
• Response to different stimulant classes varies between individuals — approximately 70% of people respond to any given stimulant, but some respond to one class and not the other.
• Non-stimulants have a different onset profile and may take weeks to become effective. They are generally not equivalent short-term substitutes for stimulants.

For comprehensive information on all ADHD medications available in Australia, see our ADHD medication guide.

The honest answer is that ADHD medication supply in Australia is likely to remain tight for the foreseeable future. Several factors suggest gradual improvement, but a complete resolution depends on structural changes that take time:

• Positive signs:**
• Additional generic manufacturers have entered the Australian market, diversifying supply sources
• The TGA has expedited approval processes for alternative suppliers during shortages
• PBS data suggests the rate of prescription growth is stabilising (though still increasing)
• Global API manufacturing capacity is expanding, with new facilities coming online

• Ongoing challenges:**
• Diagnosis rates continue to increase, meaning demand will keep growing
• Global supply chains remain concentrated among a small number of manufacturers
• Regulatory quotas in manufacturing countries can create unpredictable supply disruptions
• Australia's relatively small market means we will always be vulnerable to global supply fluctuations

What should change (Senate inquiry recommendations): The 2023 Senate inquiry recommended that the Australian Government develop a national ADHD medication supply strategy, including maintaining strategic reserves of key medications and working with international partners to secure supply agreements. Implementation of these recommendations has been slow.

• What you can do:**
• Stay informed — the TGA publishes medicine shortage reports at tga.gov.au
• Maintain a buffer supply and a backup plan with your prescriber
• Report shortages to the TGA to help them track the problem
• Support advocacy organisations pushing for better supply security

The shortage is a system-level problem that requires system-level solutions. In the meantime, proactive planning with your prescriber and pharmacist is the best defence against supply disruptions.